Takeda Forecasts Loss for Fiscal 2008 After Flurry of M&A Moves
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Takeda Pharmaceutical forecasted losses for fiscal year 2008 due in large part to recent M&A activity, and operating income and ordinary income fell in fiscal year 2007, the company announced
You may also be interested in...
Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug
TOKYO - Osaka-based Takeda and its U.S. subsidiary Millennium, jointly with a Japanese pharmaceutical venture, CanBas Co., have begun Phase II trials of malignant pleural mesothelioma drug CBP501 in the United States. The drug's advancement could eventually save millions of people that have been exposed to deadly asbestos, the company said
Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug
TOKYO - Osaka-based Takeda and its U.S. subsidiary Millennium, jointly with a Japanese pharmaceutical venture, CanBas Co., have begun Phase II trials of malignant pleural mesothelioma drug CBP501 in the United States. The drug's advancement could eventually save millions of people that have been exposed to deadly asbestos, the company said
Analyst Says FDA First-Line Approval Of Takeda/Millennium’s Velcade No Surprise
TOKYO - The U.S. FDA's approval of Millennium Pharmaceuticals' Velcade (bortezomib) injection indicated for first-line treatment of multiple myeloma comes as no surprise to those analyzing the pharmaceutical industry